• Histologically or cytologically confirmed adenocarcinoma of the prostate

• ECOG performance status 0-1

• Ability to swallow oral medications and comply with study procedures and requirements.

• Males ≥18 years

• Participants must have adequate organ and marrow function as below:

∙ Absolute neutrophil count (ANC) ≥1,500/mm3 or ≥1.5 x 109/L;

‣ Platelets ≥100,000/mm3 or ≥100 x 109/L;

‣ Hemoglobin ≥8 g/dL (may have been transfused).

‣ Estimated creatinine clearance ≥30 mL/min as calculated using the Cockcroft-Gault equation.

‣ Total serum bilirubin \<1.5 x upper limit of normal (ULN), less than 2.0 x ULN if suspected Gilbert's syndrome;

‣ Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN.

• Must be a candidate for RP

• Clinical stage cT2-4, N0-1

• Mandatory to identify tumor availability (≥10 FFPE slides, 5 µM thickness \& 1 stained H\&E slide OR tumor block)

• High-risk PCa defined as one of the following-

‣ Gleason score (GS) ≥ 4 + 3 with ≥ 6 positive systematic biopsies (SB)

⁃ GS ≥ 4 + 3 with ≥ 3 SB and prostate-specific antigen (PSA) ≥ 20 ng/mL

⁃ GS ≥ 9 in ≥ 1 SB or targeted biopsies (TB) -≥ 2 SB or TB with continuous GS ≥ 8, each with ≥ 80% involvement.